Wuxi Biologics (2269 HK)

706

Analysis

Health Care • China

Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.

Refresh

Exchange Announcement • 22 Sep 2026 16:46

Interim Report 2026

Exchange Announcement • 18 Sep 2026 21:14

Next Day Disclosure Return

Exchange Announcement • 09 Sep 2026 21:38

Next Day Disclosure Return

Exchange Announcement • 07 Sep 2026 20:53

Next Day Disclosure Return

Exchange Announcement • 04 Sep 2026 19:56

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00